Search clinical trials for: Mirvetuximab Soravtansine (IMGN853)
Total 60 results
-
University of Alabama at BirminghamRecruitingOvarian Cancer | Primary Peritoneal Cancer | Fallopian TubeUnited States
-
ImmunoGen, Inc.CompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerUnited States, Belgium, Spain, Israel, Australia, Ireland, Germany, Italy, Bulgaria, Czechia, Poland
-
University of Colorado, DenverImmunoGen, Inc.RecruitingFallopian Tube Cancer | Peritoneal Cancer | Ovary CancerUnited States
-
Alessandro SantinImmunoGen, Inc.RecruitingEndometrial CancerUnited States
-
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.RecruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerChina
-
Duke UniversityNational Comprehensive Cancer NetworkWithdrawnBreast Cancer Triple NegativeUnited States
-
Dana-Farber Cancer InstituteMerck Sharp & Dohme LLC; ImmunoGen, Inc.RecruitingEndometrial CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Breast Carcinoma | Triple-Negative Breast CarcinomaUnited States
-
ImmunoGen, Inc.RecruitingFallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Ovarian CancerUnited States, Spain, United Kingdom, Belgium, Canada, Georgia
-
ImmunoGen, Inc.Active, not recruitingOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States, France, Belgium, Spain, Ireland, Italy, Australia, Canada
-
University of OklahomaImmunoGen, Inc.WithdrawnEndometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial AdenocarcinomaUnited States
-
ImmunoGen, Inc.GOG FoundationRecruitingOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States, Korea, Republic of, Spain, Australia, Canada, United Kingdom, Italy, Belgium, Czechia, Philippines, Israel
-
Ohio State University Comprehensive Cancer CenterImmunoGen, Inc.; Clovis Oncology, Inc.Active, not recruitingBRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...United States
-
ImmunoGen, Inc.Gynecologic Oncology Group; European Network of Gynaecological Oncological...Active, not recruitingFallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal CancerUnited States, Canada, Germany, China, France, Korea, Republic of, Belgium, United Kingdom, Serbia, Spain, Australia, Israel, Italy, Taiwan, Czechia, Bulgaria, Netherlands, Portugal, Poland, Russian Federation, Ukraine
-
AGO Research GmbHRecruitingRecurrent Epithelial Ovarian, Fallopian or Peritoneal CarcinomaGermany
-
Jiangxi Qingfeng Pharmaceutical Co. Ltd.Unknown
-
ImmunoGen, Inc.Not yet recruitingRecurrent Ovarian Cancer | Folate Receptor-Alpha PositiveUnited States, Spain, Australia, Belgium, Canada, France, Ireland, Italy
-
Zai Lab (Shanghai) Co., Ltd.CompletedHER2 Positive Metastatic Breast CancerChina
-
ImmunoGen, Inc.CompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CancerUnited States, Spain, Belgium, Canada
-
Shattuck Labs, Inc.Enrolling by invitationOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal CarcinomaUnited States, United Kingdom, Spain, Canada
-
MacroGenicsNational Cancer Institute (NCI); Green Cross CorporationCompletedBreast Cancer | Gastric CancerKorea, Republic of, United States
-
MacroGenicsMerck Sharp & Dohme LLCCompletedStomach Cancer | Gastric Cancer | Esophageal CancerKorea, Republic of, United States, Taiwan, Singapore, Canada
-
ImmunoGen, Inc.Gynecologic Oncology GroupCompletedOvarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CarcinomaUnited States, France, Canada, Spain, Switzerland, Belgium, Italy, United Kingdom, Ireland, Russian Federation, Bosnia and Herzegovina, Czechia, Serbia
-
ImmunoGen, Inc.RecruitingFallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of OvaryUnited States
-
MacroGenicsZai Lab (Shanghai) Co., Ltd.Active, not recruitingGastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric CancerKorea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
MacroGenicsCompleted
-
Cairo UniversityRecruiting
-
MacroGenicsCompletedCervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid TumorsHong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
-
St. Jude Children's Research HospitalKazia Therapeutics LimitedCompletedBrain and Central Nervous System TumorsUnited States
-
BayerTerminatedSolid TumorsUnited States, Italy, France, Poland
-
MacroGenicsCompletedHER-2 Positive Breast Cancer | Metastatic NeoplasmUnited States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
-
MedSIRMacroGenics; Seagen Inc.WithdrawnAdvanced Breast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer
-
SanofiActive, not recruitingNon-squamous Non-small-cell Lung Cancer (NSQ NSCLC)Spain, United States, Brazil, Chile, Czechia, France, Hungary, Israel
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingNon-squamous Non-small-cell Lung CancerChina
-
Erasmus Medical CenterSanofiWithdrawnMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerNetherlands
-
Yale UniversityBayerCompletedPancreatic CancerUnited States
-
Biotest Pharmaceuticals CorporationBiotestCompletedMultiple MyelomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingPleural Malignant MesotheliomaUnited States, Canada
-
BayerCompletedNeoplasmsFrance, Moldova, Republic of
-
SanofiActive, not recruitingNon-squamous Non-small Cell Lung CancerBelgium, Italy, Spain, Japan, United States, France, Turkey
-
SanofiTerminatedNeoplasmFrance, United States, Belgium, Spain, Turkey
-
BayerImmunoGen and MorphoSysCompletedMesotheliomaBelgium, France, United States, Canada, Spain, Turkey, United Kingdom, Australia, Finland, Italy, Poland, Korea, Republic of, Netherlands, Russian Federation
-
National Cancer Institute (NCI)TerminatedLung NeoplasmsUnited States
-
SanofiActive, not recruitingBreast Cancer Metastatic | Pancreatic Carcinoma MetastaticSpain, Korea, Republic of, Turkey, Chile, Netherlands, Russian Federation, Taiwan, United States, Argentina, Hungary
-
SanofiActive, not recruitingAdenocarcinoma Gastric | Gastrooesophageal CancerJapan, Belgium, Korea, Republic of, Spain, Russian Federation, Turkey
-
Dana-Farber Cancer InstituteMacroGenics; Translational Breast Cancer Research ConsortiumRecruitingBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage III Breast CancerUnited States
-
Biotest Pharmaceuticals CorporationBiotestCompletedMultiple MyelomaUnited States